Immunoconjugates: lessons from animal models
- PMID: 7826901
- DOI: 10.1093/oxfordjournals.annonc.a058972
Immunoconjugates: lessons from animal models
Abstract
Monoclonal antibody-mediated cancer therapy has evolved through a challenging chain of problems and solutions. The very limited therapeutic success obtained with unarmed monoclonal antibodies has increased the interest in different antibody-based targeting strategies, and numerous preclinical and even clinical studies with immunoconjugates have now been conducted. We comment here on the messages implicit in a recent report on a doxorubicin-anti-carcinoma antibody conjugate and from several other studies.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
